Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Pain and Headache Reports
Published in: Current Pain and Headache Reports 1/2016

01-01-2016 | Chronic Daily Headache (SJ Wang, Section Editor)

Outcome of Chronic Daily Headache or Chronic Migraine

Authors: Soo-Jin Cho, Tae-Jin Song, Min Kyung Chu

Published in: Current Pain and Headache Reports | Issue 1/2016

Login to get access

Abstract

Chronic daily headache (CDH) is a common neurological condition that affects 1–4 % of the general population. Recent epidemiological studies have shown that CDH is mainly represented by chronic migraine (CM). Owing to the frequent headaches, associated symptoms, and comorbid conditions associated with CDH/CM, disability, quality of life (QoL), economic burden, and treatment outcome have become important personal and social issues. There have been several studies assessing the disability, QoL, and economic burden associated with CDH/CM. These studies, conducted in different settings, consistently reported significantly higher disability and economic burden and lower QoL among CDH/CM patients compared to patients with episodic headache (EH) or episodic migraine (EM). Treatment outcome of CDH/CM is often poor. In this review, we describe and summarize the results of relevant studies performed to date.
Literature
1.
2.
3.
Stark RJ, Ravishankar K, Siow HC, Lee KS, Pepperle R, Wang S-J. Chronic migraine and chronic daily headache in the Asia-Pacific region: a systematic review. Cephalalgia. 2013;33(4):266–83.PubMedCrossRef
4.
5.
Bigal M, Lipton R, Tepper S, Rapoport A, Sheftell F. Primary chronic daily headache and its subtypes in adolescents and adults. Neurology. 2004;63(5):843–7.PubMedCrossRef
6.
Lu S, Fuh J, Chen W, Juang K, Wang S. Chronic daily headache in Taipei, Taiwan: prevalence, follow-up and outcome predictors. Cephalalgia. 2001;21(10):980–6.PubMedCrossRef
7.
Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition (beta version). Cephalalgia. 2013;33(9):629–808.CrossRef
8.
Headache Classificaation Subcommittee of the International Headache Society. The international classification of headache disorders: 2nd edition. Cephalalgia. 2004;24 Suppl 1:9–160.
9.
Silberstein SD, Lipton RB, Dodick DW. Operational diagnostic criteria for chronic migraine: expert opinion. Headache. 2014;54(7):1258–66.PubMedCrossRef
10.
Manack AN, Buse DC, Lipton RB. Chronic migraine: epidemiology and disease burden. Curr Pain Headache Rep. 2011;15(1):70–8.PubMedCrossRef
11.
Natoli J, Manack A, Dean B, Butler Q, Turkel C, Stovner L, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2009;30(5):599–609.
12.••
Blumenfeld AM, Varon SF, Wilcox TK, Buse DC, Kawata AK, Manack A, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2011;31(3):301–15. This international web-based cross-sectional study with participants from ten countries shed on the light of the severe disability of chronic migraine.PubMedCrossRef
13.
Chong CD, Dodick DW, Schlaggar BL, Schwedt TJ. Atypical age-related cortical thinning in episodic migraine. Cephalalgia. 2014;34(14):1115–24.PubMedCrossRef
14.
Leonardi M, Raggi A. Burden of migraine: international perspectives. Neurol Sci. 2013;34 Suppl 1:S117–8.PubMedCrossRef
15.
Katsarava Z, Buse DC, Manack AN, Lipton RB. Defining the differences between episodic migraine and chronic migraine. Curr Pain Headache Rep. 2012;16(1):86–92.PubMedPubMedCentralCrossRef
16.
17.••
Lanteri-Minet M, Duru G, Mudge M, Cottrell S. Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review. Cephalalgia. 2011;31(7):837–50. This article showed extensive reviews of quality of life, disability, and economic burden of chronic daily headache or chronic migraine with elegant figure and tables.PubMedCrossRef
18.
Bigal ME, Rapoport AM, Lipton RB, Tepper SJ, Sheftell FD. Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: a comparison of chronic migraine with episodic migraine. Headache. 2003;43(4):336–42.PubMedCrossRef
19.
Steiner TJ, Paemeleire K, Jensen R, Valade D, Savi L, Lainez MJ, et al. European principles of management of common headache disorders in primary care. J Headache Pain. 2007;8 Suppl 1:S3–47.PubMed
20.
Fiane I, Haugland ME, Stovner LJ, Zwart JA, Bovim G, Hagen K. Sick leave is related to frequencies of migraine and non-migrainous headache—the HUNT Study. Cephalalgia. 2006;26(8):960–7.PubMedCrossRef
21.
Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology. 2008;71(8):559–66.PubMedCrossRef
22.
Lanteri-Minet M, Auray JP, El Hasnaoui A, Dartigues JF, Duru G, Henry P, et al. Prevalence and description of chronic daily headache in the general population in France. Pain. 2003;102(1–2):143–9.PubMedCrossRef
23.
D’Amico D, Grazzi L, Usai S, Rigamonti A, Curone M, Bussone G. Disability pattern in chronic migraine with medication overuse: a comparison with migraine without aura. Headache. 2005;45(5):553–60.PubMedCrossRef
24.•
Lanteri-Minet M. Economic burden and costs of chronic migraine. Curr Pain Headache Rep. 2014;18(1):1–6. An updated review on economic burden and costs of chronic migraine.CrossRef
25.
26.
Bussone G, Usai S, Grazzi L, Rigamonti A, Solari A, D’Amico D. Disability and quality of life in different primary headaches: results from Italian studies. Neurol Sci. 2004;25 Suppl 3:S105–7.PubMedCrossRef
27.
Yu S, Liu R, Zhao G, Yang X, Qiao X, Feng J, et al. The prevalence and burden of primary headaches in China: a population-based door-to-door survey. Headache. 2012;52(4):582–91.PubMedCrossRef
28.
Queiroz LP, Silva Junior AA. The prevalence and impact of headache in Brazil. Headache. 2015;55 Suppl 1:32–8.PubMedCrossRef
29.
Zebenholzer K, Andree C, Lechner A, Broessner G, Lampl C, Luthringshausen G, et al. Prevalence, management and burden of episodic and chronic headaches—a cross-sectional multicentre study in eight Austrian headache centres. J Headache Pain. 2015;16(1):531.PubMedCrossRef
30.
D’Amico D, Usai S, Grazzi L, Rigamonti A, Solari A, Leone M, et al. Quality of life and disability in primary chronic daily headaches. Neurol Sci. 2003;24 Suppl 2:S97–100.PubMed
31.
Buse DC, Manack AN, Fanning KM, Serrano D, Reed ML, Turkel CC, et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache. 2012;52(10):1456–70.PubMedCrossRef
32.•
Abu Bakar N, Tanprawate S, Lambru G, Torkamani M, Jahanshahi M, Matharu M. Quality of life in primary headache disorders: a review. Cephalalgia. 2015:0333102415580099. Recent update of quality of life of migraine, tension-type headache, and chronic daily headache focusing with detailed description of assessing instrument and study quality .
33.
Adams AM, Serrano D, Buse DC, Reed ML, Marske V, Fanning KM, et al. The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results. Cephalalgia. 2015;35(7):563–78.PubMedPubMedCentralCrossRef
34.
Bagley CL, Rendas-Baum R, Maglinte GA, Yang M, Varon SF, Lee J, et al. Validating Migraine-Specific Quality of Life Questionnaire v2.1 in episodic and chronic migraine. Headache. 2012;52(3):409–21.PubMedCrossRef
35.
da Rocha NS, Power MJ, Bushnell DM, Fleck MP. The EUROHIS-QOL 8-item index: comparative psychometric properties to its parent WHOQOL-BREF. Value Health. 2012;15(3):449–57.PubMedCrossRef
36.
Ware Jr JE, Sherbourne CD, The MOS. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–83.PubMedCrossRef
37.
Duru G, Auray JP, Gaudin AF, Dartigues JF, Henry P, Lanteri-Minet M, et al. Impact of headache on quality of life in a general population survey in France (GRIM2000 Study). Headache. 2004;44(6):571–80.PubMedCrossRef
38.
39.
Guitera V, Munoz P, Castillo J, Pascual J. Quality of life in chronic daily headache: a study in a general population. Neurology. 2002;58(7):1062–5.PubMedCrossRef
40.
Meletiche DM, Lofland JH, Young WB. Quality-of-life differences between patients with episodic and transformed migraine. Headache. 2001;41(6):573–8.PubMedCrossRef
41.
Wang SJ, Fuh JL, Lu SR, Juang KD. Quality of life differs among headache diagnoses: analysis of SF-36 survey in 901 headache patients. Pain. 2001;89(2–3):285–92.PubMedCrossRef
42.
43.
Manzoni GC, Torelli P. Epidemiological classification and social impact of chronic headache. Intern Emerg Med. 2010;5 Suppl 1:S1–5.PubMedCrossRef
44.
Cavallini A, Micieli G, Bussone G, Rossi F, Nappi G. Headache and quality of life. Headache. 1995;35(1):29–35.PubMedCrossRef
45.
Steiner TJ, Birbeck GL, Jensen R, Katsarava Z, Martelletti P, Stovner LJ. The global campaign, world health organization and lifting the burden: collaboration in action. J Headache Pain. 2011;12(3):273–4.PubMedPubMedCentralCrossRef
46.
Steiner TJ, Gururaj G, Andree C, Katsarava Z, Ayzenberg I, Yu SY, et al. Diagnosis, prevalence estimation and burden measurement in population surveys of headache: presenting the HARDSHIP questionnaire. J Headache Pain. 2014;15:3.PubMedPubMedCentralCrossRef
47.
Buse DC, Manack A, Serrano D, Turkel C, Lipton RB. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry. 2010;81(4):428–32.PubMedCrossRef
48.
Lipton R, Scher A, Steiner T, Bigal M, Kolodner K, Liberman J, et al. Patterns of health care utilization for migraine in England and in the United States. Neurology. 2003;60(3):441–8.PubMedCrossRef
49.
Sanderson JC, Devine EB, Lipton RB, Bloudek LM, Varon SF, Blumenfeld AM, et al. Headache-related health resource utilisation in chronic and episodic migraine across six countries. J Neurol Neurosurg Psychiatry. 2013;84(12):1309–17.PubMedPubMedCentralCrossRef
50.
Munakata J, Hazard E, Serrano D, Klingman D, Rupnow MF, Tierce J, et al. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2009;49(4):498–508.PubMedCrossRef
51.
Wang SJ, Wang PJ, Fuh JL, Peng KP, Ng K. Comparisons of disability, quality of life, and resource use between chronic and episodic migraineurs: a clinic-based study in Taiwan. Cephalalgia. 2013;33(3):171–81.PubMedCrossRef
52.
Park JW, Moon HS, Kim JM, Lee KS, Chu MK. Chronic daily headache in Korea: prevalence, clinical characteristics, medical consultation and management. J Clin Neurol. 2014;10(3):236–43.PubMedPubMedCentralCrossRef
53.
Stewart WF, Wood GC, Manack A, Varon SF, Buse DC, Lipton RB. Employment and work impact of chronic migraine and episodic migraine. J Occup Environ Med. 2010;52(1):8–14.PubMedCrossRef
54.
Lionetto L, Negro A, Palmisani S, Gentile G, Fiore MRD, Mercieri M, et al. Emerging treatment for chronic migraine and refractory chronic migraine. Expert Opin Emerg Drugs. 2012;17(3):393–406.PubMedCrossRef
55.•
Mulleners WM, McCrory DC, Linde M. Antiepileptics in migraine prophylaxis: an updated Cochrane review. Cephalalgia. 2015;35(1):51–62. A concise and updated review of migraine and chronic migraine prophylaxis.PubMedCrossRef
56.
Bigal M, Rapoport A, Sheftell F, Tepper D, Tepper S. Memantine in the preventive treatment of refractory migraine. Headache. 2008;48(9):1337–42.PubMedCrossRef
57.
Calandre EP, Garcia-Leiva JM, Rico-Villademoros F, Vilchez JS, Rodriguez-Lopez CM. Pregabalin in the treatment of chronic migraine: an open-label study. Clin Neuropharmacol. 2010;33(1):35–9.PubMedCrossRef
58.
59.
Magalhães E, Menezes C, Cardeal M, Melo A. Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine. Clin Neurol Neurosurg. 2010;112(6):463–6.PubMedCrossRef
60.
Pascual-Gómez J, Alañá-García M, Oterino A, Leira R, Láinez-Andrés J. Preventive treatment of chronic migraine with zonisamide: a study in patients who are refractory or intolerant to topiramate. Rev Neurol. 2007;47(9):449–51.
61.
Saper JR, Lake AE, Cantrell DT, Winner PK, White JR. Chronic daily headache prophylaxis with tizanidine: a double‐blind, placebo‐controlled, multicenter outcome study. Headache. 2002;42(6):470–82.PubMedCrossRef
62.
Yurekli VA, Akhan G, Kutluhan S, Uzar E, Koyuncuoglu HR, Gultekin F. The effect of sodium valproate on chronic daily headache and its subgroups. J Headache Pain. 2008;9(1):37–41.PubMedPubMedCentralCrossRef
63.
Pistoia F, Sacco S, Carolei A. Behavioral therapy for chronic migraine. Curr Pain Headache Rep. 2013;17(1):1–8.CrossRef
64.
Reed K, Black S, Banta C, Will K. Combined occipital and supraorbital neurostimulation for the treatment of chronic migraine headaches: initial experience. Cephalalgia. 2009;30(3):260–71.
65.
Yang C, Chang M, Liu P, Li T, Hsieh C, Hwang K, et al. Acupuncture versus topiramate in chronic migraine prophylaxis: a randomized clinical trial. Cephalalgia. 2011;31(15):1510–21.PubMedCrossRef
66.
Diener H, Bussone G, Van Oene J, Lahaye M, Schwalen S, Goadsby P. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007;27(7):814–23.PubMedCrossRef
67.
Silberstein SD, Lipton RB, Dodick DW, Freitag FG, Ramadan N, Mathew N, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double‐blind, placebo‐controlled trial. Headache. 2007;47(2):170–80.PubMedCrossRef
68.
Brandes JL, Saper JR, Diamond M, Couch JR, Lewis DW, Schmitt J, et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA. 2004;291(8):965–73.PubMedCrossRef
69.
Storey J, Calder C, Hart D, Potter D. Topiramate in migraine prevention: a double‐blind, placebo‐controlled study. Headache. 2001;41(10):968–75.PubMedCrossRef
70.
Aurora S, Dodick D, Turkel C, DeGryse R, Silberstein S, Lipton R, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30(7):793–803.PubMedCrossRef
71.
Diener H, Dodick D, Aurora S, Turkel C, DeGryse R, Lipton R, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30(7):804–14.PubMedCrossRef
72.
Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double‐blind, randomized, placebo‐controlled phases of the PREEMPT clinical program. Headache. 2010;50(6):921–36.PubMedCrossRef
73.
Naumann M, So Y, Argoff C, Childers M, Dykstra D, Gronseth G, et al. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review) Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70(19):1707–14.PubMedCrossRef
74.
Spira PJ, Beran RG. Gabapentin in the prophylaxis of chronic daily headache: a randomized, placebo-controlled study. Neurology. 2003;61(12):1753–9.PubMedCrossRef
75.
Schulman EA, Lee Peterlin B, Lake AE, Lipton RB, Hanlon A, Siegel S, et al. Defining refractory migraine: results of the RHSIS Survey of American Headache Society members. Headache. 2009;49(4):509–18.PubMedCrossRef
76.
77.
Dodick DW, Silberstein SD, Reed KL, Deer TR, Slavin KV, Huh B, et al. Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: long-term results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia. 2014;35(4):344–58.PubMedCrossRef
78.
DaSilva AF, Mendonca ME, Zaghi S, Lopes M, DosSantos MF, Spierings EL, et al. tDCS‐Induced analgesia and electrical fields in pain‐related neural networks in chronic migraine. Headache. 2012;52(8):1283–95.PubMedPubMedCentralCrossRef
Metadata
Title
Outcome of Chronic Daily Headache or Chronic Migraine
Authors
Soo-Jin Cho
Tae-Jin Song
Min Kyung Chu
Publication date
01-01-2016
Publisher
Springer US
Published in
Current Pain and Headache Reports / Issue 1/2016
Print ISSN: 1531-3433
Electronic ISSN: 1534-3081
DOI
https://doi.org/10.1007/s11916-015-0534-8

Other articles of this Issue 1/2016

Current Pain and Headache Reports 1/2016 Go to the issue

Chronic Daily Headache (SJ Wang, Section Editor)

Update of Inpatient Treatment for Refractory Chronic Daily Headache

Chronic Daily Headache (SJ Wang, Section Editor)

Psychological Therapy in Adolescents with Chronic Daily Headache

Childhood and Adolescent Headache (S Evers, Section Editor)

Prophylactic Drug Treatment of Migraine in Children and Adolescents: An Update

Chronic Daily Headache (SJ Wang, Section Editor)

Recent Approaches and Development of Acupuncture on Chronic Daily Headache

Chronic Daily Headache (SJ Wang, Section Editor)

Update on the Pharmacological Treatment of Chronic Migraine

Childhood and Adolescent Headache (S Evers, Section Editor)

Pediatric Aspects of Headache Classification in the International Classification of Headache Disorders—3 (ICHD-3 beta version)